TY - JOUR
T1 - Clinical study of sitafloxacin in male nongonococcal urethritis
AU - Kawada, Yukimichi
AU - Matsumoto, Tetsuro
AU - Onodera, Shoichi
AU - Kaku, Mitsuo
AU - Hori, Seiji
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/4
Y1 - 2008/4
N2 - The clinical efficacy and safety of sitafloxacin(STFX), a fluoroquinolone compound, were evaluated in male patients with nongonococcal urethritis treated orally 7 days with 50 mg b.i.d, of STFX. Clinical efficacy was evaluated based on criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection (draft, fourth edition). Overall clinical efficacy was 88.6% (31/35) for nongonococcal urethritis and, by diagnosis, 85.2% (23/27) for nongonococcal-chlamydial urethritis, 100% (7/7) for Mycoplasma genitalium-negative nongonococcal-nonchlamydial urethritis, and excellent in 1 case with M. genitalium-positive nongonococcal urethritis. Eradication by microorganism was 96.0% (24/25) for Chlamydia trachomatis, 88.9% (8/9) for Ureaplasma urealyticum, and 100% (7/7) for Ureaplasma parvum. Two of 3 strains of M. genitalium were eradicated. The incidence of adverse reactions was 27.3% (12/44), the most common being diarrhea. All symptoms were mild or moderate. Results suggest that STFX was effective and safe in the treatment of male nongonococcal urethritis.
AB - The clinical efficacy and safety of sitafloxacin(STFX), a fluoroquinolone compound, were evaluated in male patients with nongonococcal urethritis treated orally 7 days with 50 mg b.i.d, of STFX. Clinical efficacy was evaluated based on criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection (draft, fourth edition). Overall clinical efficacy was 88.6% (31/35) for nongonococcal urethritis and, by diagnosis, 85.2% (23/27) for nongonococcal-chlamydial urethritis, 100% (7/7) for Mycoplasma genitalium-negative nongonococcal-nonchlamydial urethritis, and excellent in 1 case with M. genitalium-positive nongonococcal urethritis. Eradication by microorganism was 96.0% (24/25) for Chlamydia trachomatis, 88.9% (8/9) for Ureaplasma urealyticum, and 100% (7/7) for Ureaplasma parvum. Two of 3 strains of M. genitalium were eradicated. The incidence of adverse reactions was 27.3% (12/44), the most common being diarrhea. All symptoms were mild or moderate. Results suggest that STFX was effective and safe in the treatment of male nongonococcal urethritis.
KW - Clinical trial
KW - Nongonococcal urethritis
KW - Sitafloxacin
UR - http://www.scopus.com/inward/record.url?scp=43449139139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43449139139&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:43449139139
VL - 56
SP - 130
EP - 138
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
IS - SUPPL. 1
ER -